RosettaCommons/UTexasAptamer huggingface dataset:
Aptamer: CB-42
Target: Cibacron Blue 3GA
Type of nucleic acid: ssRNA
Sequence: 5'GGGAGAAUUCCCGCGGCAGAAGCCCACCUGGCUUUGAACUCUAUGUUAUUGGGUGGGGGAAACUUAAGAAAACUACCACCCUUCAACAUUACCGCCCUUCAGCCUGCCAGCGCCCUGCAGCCCGGGAAGCUU3'
Sequence length: 132
GC content: 0.5606060606060606
Affinity: Kd~600µM
Pool type: 5'-GGGAGAATTCCCGCGG-N98-CTGCAGCCCGGGAAGCTT-3'
Pool random region: 98
Binding buffer/conditions: 0.6 ml of 0.5 M LiCI, 20 mM Tris-HCI, pH 7.6, 1 mM MgCl2
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.6
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " Isolate RNAs that bind to several dyes that appear to mimic metabolic cofactors. For example, Cibacron Blue binds tightly to the NADbinding site of many dehydrogenases and Cibacron Blue columns have been used for purification of these proteins by affinity chromatography. The experiments described here used Cibacron Blue 3GA (CB), Reactive Red 120 (R), Reactive Yellow 86 (Y), Reactive Brown 10 (BR), Reactive Green 19 (GR) and Reactive Blue 4 (B4) attached to cross-linked, beaded agarose. We chose these molecules because they have many possible hydrogen-bond donor and acceptor groups as well as planar surfaces for stacking interactions."
Additional information: The aptamer was reported in DNA (include thymine nucleotide, instead of Uridine). The T was changed to U to match the discription of paper content.
DNA library/pool was used as a template to generate the RNA pool used in the selection. A T7 promoter sequence might be necessary to use this DNA library/pool as a template to generate the RNA pool in the selection.
Reference (1990, Nature ): Ellington, A. D., & Szostak, J. W. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature, 346(6287), 818–822. https://doi.org/10.1038/346818a0
Aptamer: B4-25
Target: Reactive Blue 4
Type of nucleic acid: ssRNA
Sequence: 5'GGGAGAAUUCCCGCGGCGUUGGCCCAGGAUAAUAGGACGAAAUCCGAAAAAUCCGUACCCAACAUAGAACCCCCCCAGCGCUCACACGGACGCCCCAUUACGGCUAACCGAACGCCUGCAGCCCGGGAAGCUU3'
Sequence length: 133
GC content: 0.5939849624060151
Affinity: Kd<100µM
Pool type: 5'-GGGAGAATTCCCGCGG-N97-CTGCAGCCCGGAAGCTT-3'
Pool random region: 97
Binding buffer/conditions: 0.6 ml of 0.5 M LiCI, 20 mM Tris-HCI, pH 7.6, 1 mM MgCl3
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.6
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " Isolate RNAs that bind to several dyes that appear to mimic metabolic cofactors. For example, Cibacron Blue binds tightly to the NADbinding site of many dehydrogenases and Cibacron Blue columns have been used for purification of these proteins by affinity chromatography. The experiments described here used Cibacron Blue 3GA (CB), Reactive Red 120 (R), Reactive Yellow 86 (Y), Reactive Brown 10 (BR), Reactive Green 19 (GR) and Reactive Blue 4 (B4) attached to cross-linked, beaded agarose. We chose these molecules because they have many possible hydrogen-bond donor and acceptor groups as well as planar surfaces for stacking interactions."
Additional information: DNA library/pool was used as a template to generate the RNA pool used in the selection. A T7 promoter sequence might be necessary to use this DNA library/pool as a template to generate the RNA pool in the selection.

Reference (1990, Nature ): Ellington, A. D., & Szostak, J. W. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature, 346(6287), 818–822. https://doi.org/10.1038/346818a0
Aptamer: wild type
Target: T4 DNA polymerase (gp43)
Type of nucleic acid: ssRNA
Sequence: 5'GAAUUGUGGUGUUGGCUCCCUAUAGUGAGUCGUAUUAAUAUUCCUUAGUUUUAUAGCCCAAUAACUCAGGCUCUUGAUUGGUUUUCAAUAGAGAUAUAAAAUUCUUUUCAUAG3'
Sequence length: 113
GC content: 0.336283185840708
Affinity: Kd: 4.8 nM
Pool type: 5'-GAATTGTGGTGTTGGCTCCCTATAGTGAGTCGTATTA-ATATTCCTTAGTTTTATAGCCC-N9-AGGCTCTTGATTG-GTTTTCAATAGAGATATAAAATTCTTTTCATAG-3'
Pool random region: 9
Binding buffer/conditions: Not reported
Buffer type: Not Reported
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " We have previously shown that the RNA target of T4 DNA polymerase selectively inhibits its replicative function.Thus,the products of SELEX can affect the activity of the protein to which they have been fit. We expect that, at the very least,nucleic acid ligands that inhibit replicative proteins of epidemiologically important infections can be likewise evolved."
Additional information: DNA library/pool was used as a template to generate the RNA pool used in the selection. A T7 promoter sequence might be necessary to use this DNA library/pool as a template to generate the RNA pool in the selection.

Reference (1990, Science ): Tuerk, C., & Gold, L. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science (New York, N.Y.), 249(4968), 505–510. https://doi.org/10.1126/science.2200121
Aptamer: major variant
Target: T4 DNA polymerase (gp43)
Type of nucleic acid: ssRNA
Sequence: 5'GAAUUGUGGUGUUGGCUCCCUAUAGUGAGUCGUAUUAAUAUUCCUUAGUUUUAUAGCCCAGCAACCUAGGCUCUUGAUUGGUUUUCAAUAGAGAUAUAAAAUUCUUUUCAUAG3'
Sequence length: 113
GC content: 0.3539823008849557
Affinity: Kd: 4.8 nM
Pool type: 5'-GAATTGTGGTGTTGGCTCCCTATAGTGAGTCGTATTA-ATATTCCTTAGTTTTATAGCCC-N9-AGGCTCTTGATTG-GTTTTCAATAGAGATATAAAATTCTTTTCATAG-3'
Pool random region: 9
Binding buffer/conditions: Not reported
Buffer type: Not Reported
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " We have previously shown that the RNA target of T4 DNA polymerase selectively inhibits its replicative function.Thus,the products of SELEX can affect the activity of the protein to which they have been fit. We expect that, at the very least,nucleic acid ligands that inhibit replicative proteins of epidemiologically important infections can be likewise evolved."
Additional information: DNA library/pool was used as a template to generate the RNA pool used in the selection. A T7 promoter sequence might be necessary to use this DNA library/pool as a template to generate the RNA pool in the selection.

Reference (1990, Science ): Tuerk, C., & Gold, L. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science (New York, N.Y.), 249(4968), 505–510. https://doi.org/10.1126/science.2200121
Aptamer: 15 mer (colloquially known as Bock DNA Aptamer)
Target: Thrombin (Sigma), Human
Type of nucleic acid: ssDNA
Sequence: 5'GGTTGGTGTGGTTGG3'
Sequence length: 15
GC content: 0.6
Affinity: Kd: 25-200 nM
Pool type: 5'-CGTACGGTCGACGCTAGC-60N-CACGTGGAGCTCGGATCC-3'
Pool random region: 60
Binding buffer/conditions: 19 mM Tris-acetate, pH 7.4, 140 mM NaCI, 5 mM KCI, 1 mM CaCI2, 1 mM MgCI2
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and therapeutic: "We are at present investigating the aptamer-binding site on thrombin and analysing the binding sequences of individual aptamers in an effort to understand the base relationships that mediate binding and inhibition, our long-term interest being to develop diagnostics and therapeutic agents."
Additional information: Presumed minimized variant was found 
Reference (1992, Nature ): Bock, L. C., Griffin, L. C., Latham, J. A., Vermaas, E. H., & Toole, J. J. (1992). Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature, 355(6360), 564–566. https://doi.org/10.1038/355564a0
Aptamer: ligand 1.1
Target: Human imunnodeficiency virus type 1 reverse transcriptase (HIV-1-RT)
Type of nucleic acid: ssRNA
Sequence: 5'GGGAGCAUCAGACUUUUAAUCUGACAAUCAAGAAUUCCGUUUUCAGUCGGGAAAAACUGAACAAUCUAUGAAAGAAUUUUAUAUCUCUAUUGAAAC3'
Sequence length: 96
GC content: 0.3333333333333333
Affinity: Kd: 5 nM
Pool type: 5'-GGGAGCAUCAGACUUUUAAUCUGACAAUCAAG-N32-AUCUAUGAAAGAAUUUUAUAUCUCUAUUGAAAC-3'
Pool random region: 32
Binding buffer/conditions: 200 mM KOAc/50 mM Tris-HCI, pH 7.7/10 mM dithiothreitol
Buffer type: Tris Buffers
pH: 7.7
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " Demonstrated that at least one of the ligands inhibits cDNA synthesis by HIV reverse transcriptase but falls to inhibit other reverse transcriptases. These exeriments highlight the power of SELEX to yield hlghiy spedfc ligands that reduce the activity of target proteins. Such ligands may provide therapeutic reagents for viral and' other dies."
Reference (1992, Proc Natl Acad Sci U S A ): Tuerk, C., MacDougal, S., & Gold, L. (1992). RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase. Proceedings of the National Academy of Sciences of the United States of America, 89(15), 6988–6992. https://doi.org/10.1073/pnas.89.15.6988
Aptamer: ligand 1.3a
Target: Human imunnodeficiency virus type 1 reverse transcriptase (HIV-1-RT)
Type of nucleic acid: ssRNA
Sequence: 5'GGGAGCAUCAGACUUUUAAUCUGACAAUCAAGAAUAUCUUCCGAAGCCGAACGGGAAAACCGGCAUCUAUGAAAGAAUUUUAUCUCUAUUGAAAC3'
Sequence length: 95
GC content: 0.3894736842105263
Affinity: Kd: 5 nM
Pool type: 5'-GGGAGCAUCAGACUUUUAAUCUGACAAUCAA-N32-AUCUAUGAAAGAAUUUUAUCUCUAUUGAAAC-3'
Pool random region: 32
Binding buffer/conditions: 200 mM KOAc/50 mM Tris-HCI, pH 7.7/10 mM dithiothreitol
Buffer type: Tris Buffers
pH: 7.7
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " Demonstrated that at least one of the ligands inhibits cDNA synthesis by HIV reverse transcriptase but falls to inhibit other reverse transcriptases. These exeriments highlight the power of SELEX to yield hlghiy spedfc ligands that reduce the activity of target proteins. Such ligands may provide therapeutic reagents for viral and' other dies."
Reference (1992, Proc Natl Acad Sci U S A ): Tuerk, C., MacDougal, S., & Gold, L. (1992). RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase. Proceedings of the National Academy of Sciences of the United States of America, 89(15), 6988–6992. https://doi.org/10.1073/pnas.89.15.6988
Aptamer: 5A
Target: Basic fibroblast growth factor (bFGF)
Type of nucleic acid: ssRNA
Sequence: 5'GGGAGCUCAGAAUAAACGCUCAAAUCUCCUCCCGUCGAAGCUAACCUGGCCACUUCGACAUGAGGCCCGGAUCCGGC3'
Sequence length: 77
GC content: 0.5844155844155844
Affinity: Kd: 23 ± 3 nM
Pool type: 5'-GGGAGCUCAGAAUAAACGCUCAA-N30-UUCGACAUGAGGCCCGGAUCCGGC-3'
Pool random region: 30
Binding buffer/conditions: PBS = 10.1 mMNa2HPO4, 1.8 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH 7.4
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: 18000 Da
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " Describe and characterize a set of high-affinity RNA ligands for bFGF that were selected from a pool of 10^14 molecules and show that these ligands inhibit binding of the growth factor to its cell-surface receptors. The idea that bFGF antagonists may have useful medicinal applications is not new (reviewed in ref. 5). bFGF is believed to play a key role in the development of smooth-muscle cell lesions following vascular injury. Overexpression of bFGF (and other members of the FGF family) is correlated with many malignant disorders"
Reference (1993, Proc Natl Acad Sci U S A ): Jellinek, D., Lynott, C. K., Rifkin, D. B., & Janjić, N. (1993). High-affinity RNA ligands to basic fibroblast growth factor inhibit receptor binding. Proceedings of the National Academy of Sciences of the United States of America, 90(23), 11227–11231. https://doi.org/10.1073/pnas.90.23.11227
Aptamer: 7A
Target: Basic fibroblast growth factor (bFGF)
Type of nucleic acid: ssRNA
Sequence: 5'GGGAGCUCAGAAUAAACGCUCAAUCGGCGAGCUAACCAAGACACUCGCUGCACUUCGACAUGAGGCCCGGAUCCGGC3'
Sequence length: 77
GC content: 0.5844155844155844
Affinity: Kd: 5.0 ± 0.5 nM
Pool type: 5'-GGGAGCUCAGAAUAAACGCUCAA-N30-UUCGACAUGAGGCCCGGAUCCGGC-3'
Pool random region: 30
Binding buffer/conditions: PBS = 10.1 mMNa2HPO4, 1.8 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH 7.4
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: 18001 Da
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " Describe and characterize a set of high-affinity RNA ligands for bFGF that were selected from a pool of 10^14 molecules and show that these ligands inhibit binding of the growth factor to its cell-surface receptors. The idea that bFGF antagonists may have useful medicinal applications is not new (reviewed in ref. 5). bFGF is believed to play a key role in the development of smooth-muscle cell lesions following vascular injury. Overexpression of bFGF (and other members of the FGF family) is correlated with many malignant disorders"
Reference (1993, Proc Natl Acad Sci U S A ): Jellinek, D., Lynott, C. K., Rifkin, D. B., & Janjić, N. (1993). High-affinity RNA ligands to basic fibroblast growth factor inhibit receptor binding. Proceedings of the National Academy of Sciences of the United States of America, 90(23), 11227–11231. https://doi.org/10.1073/pnas.90.23.11227
Aptamer: 13A
Target: Basic fibroblast growth factor (bFGF)
Type of nucleic acid: ssRNA
Sequence: 5'GGGAGCUCAGAAUAAACGCUCAAACCCGCGGCCUCCGAAGCUAACCAGGACACUUCGACAUGAGGCCCGGAUCCGGC3'
Sequence length: 77
GC content: 0.6103896103896104
Affinity: Kd: 3.2 ± 0.5 nM
Pool type: 5'-GGGAGCUCAGAAUAAACGCUCAA-N30-UUCGACAUGAGGCCCGGAUCCGGC-3'
Pool random region: 30
Binding buffer/conditions: PBS = 10.1 mMNa2HPO4, 1.8 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH 7.4
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: 18002 Da
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " Describe and characterize a set of high-affinity RNA ligands for bFGF that were selected from a pool of 10^14 molecules and show that these ligands inhibit binding of the growth factor to its cell-surface receptors. The idea that bFGF antagonists may have useful medicinal applications is not new (reviewed in ref. 5). bFGF is believed to play a key role in the development of smooth-muscle cell lesions following vascular injury. Overexpression of bFGF (and other members of the FGF family) is correlated with many malignant disorders"
Reference (1993, Proc Natl Acad Sci U S A ): Jellinek, D., Lynott, C. K., Rifkin, D. B., & Janjić, N. (1993). High-affinity RNA ligands to basic fibroblast growth factor inhibit receptor binding. Proceedings of the National Academy of Sciences of the United States of America, 90(23), 11227–11231. https://doi.org/10.1073/pnas.90.23.11227
Aptamer: 14A
Target: Basic fibroblast growth factor (bFGF)
Type of nucleic acid: ssRNA
Sequence: 5'GGGAGCUCAGAAUAAACGCUCAAUGGGUGCUAACCAGGACACACCCACGCUGUUUCGACAUGAGGCCCGGAUCCGGC3'
Sequence length: 77
GC content: 0.5844155844155844
Affinity: Kd: 3.0 ± 0.5 nM
Pool type: 5'-GGGAGCUCAGAAUAAACGCUCAA-N30-UUCGACAUGAGGCCCGGAUCCGGC-3'
Pool random region: 30
Binding buffer/conditions: PBS = 10.1 mMNa2HPO4, 1.8 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH 7.4
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: 18003 Da
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " Describe and characterize a set of high-affinity RNA ligands for bFGF that were selected from a pool of 10^14 molecules and show that these ligands inhibit binding of the growth factor to its cell-surface receptors. The idea that bFGF antagonists may have useful medicinal applications is not new (reviewed in ref. 5). bFGF is believed to play a key role in the development of smooth-muscle cell lesions following vascular injury. Overexpression of bFGF (and other members of the FGF family) is correlated with many malignant disorders"
Reference (1993, Proc Natl Acad Sci U S A ): Jellinek, D., Lynott, C. K., Rifkin, D. B., & Janjić, N. (1993). High-affinity RNA ligands to basic fibroblast growth factor inhibit receptor binding. Proceedings of the National Academy of Sciences of the United States of America, 90(23), 11227–11231. https://doi.org/10.1073/pnas.90.23.11227
Aptamer: 21A
Target: Basic fibroblast growth factor (bFGF)
Type of nucleic acid: ssRNA
Sequence: 5'GGGAGCUCAGAAUAAACGCUCAAUGGGUGCUUAACCAGGCCACACCCUGCUGUUUCGACAUGAGGCCCGGAUCCGGC3'
Sequence length: 77
GC content: 0.5844155844155844
Affinity: Kd: 8.1 ± 0.8 nM
Pool type: 5'-GGGAGCUCAGAAUAAACGCUCAA-N30-UUCGACAUGAGGCCCGGAUCCGGC-3'
Pool random region: 30
Binding buffer/conditions: PBS = 10.1 mMNa2HPO4, 1.8 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH 7.4
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: 18004 Da
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " Describe and characterize a set of high-affinity RNA ligands for bFGF that were selected from a pool of 10^14 molecules and show that these ligands inhibit binding of the growth factor to its cell-surface receptors. The idea that bFGF antagonists may have useful medicinal applications is not new (reviewed in ref. 5). bFGF is believed to play a key role in the development of smooth-muscle cell lesions following vascular injury. Overexpression of bFGF (and other members of the FGF family) is correlated with many malignant disorders"
Reference (1993, Proc Natl Acad Sci U S A ): Jellinek, D., Lynott, C. K., Rifkin, D. B., & Janjić, N. (1993). High-affinity RNA ligands to basic fibroblast growth factor inhibit receptor binding. Proceedings of the National Academy of Sciences of the United States of America, 90(23), 11227–11231. https://doi.org/10.1073/pnas.90.23.11227
Aptamer: 12A
Target: Basic fibroblast growth factor (bFGF)
Type of nucleic acid: ssRNA
Sequence: 5'GGGAGAUGCCUGUCGAGCAUGCUGGGGGCAACGCUACAGACAAGUGCACCCAACGUAGCUAAACAGCUUUGUCGACGGG3'
Sequence length: 79
GC content: 0.5822784810126582
Affinity: Kd: exhibits biphasic binding, 0.51 ± 0.13 nM, 60 ± 52 nM
Pool type: 5'-GGGAGAUGCCUGUCGAGCAUGCUG-N30-GUAGCUAAACAGCUUUGUCGACGGG-3'
Pool random region: 30
Binding buffer/conditions: PBS = 10.1 mMNa2HPO4, 1.8 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH 7.4
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: 18005 Da
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " Describe and characterize a set of high-affinity RNA ligands for bFGF that were selected from a pool of 10^14 molecules and show that these ligands inhibit binding of the growth factor to its cell-surface receptors. The idea that bFGF antagonists may have useful medicinal applications is not new (reviewed in ref. 5). bFGF is believed to play a key role in the development of smooth-muscle cell lesions following vascular injury. Overexpression of bFGF (and other members of the FGF family) is correlated with many malignant disorders"
Reference (1993, Proc Natl Acad Sci U S A ): Jellinek, D., Lynott, C. K., Rifkin, D. B., & Janjić, N. (1993). High-affinity RNA ligands to basic fibroblast growth factor inhibit receptor binding. Proceedings of the National Academy of Sciences of the United States of America, 90(23), 11227–11231. https://doi.org/10.1073/pnas.90.23.11227
Aptamer: 26At
Target: Basic fibroblast growth factor (bFGF)
Type of nucleic acid: ssRNA
Sequence: 5'GGUGAAGGCAACGUAUAGGCAAGCACACUUCACC3'
Sequence length: 34
GC content: 0.5294117647058824
Affinity: Kd: ~0.19 ± 0.02 nM
Pool type: 5'-GGGAGAUGCCUGUCGAGCAUGCUG-N30-GUAGCUAAACAGCUUUGUCGACGGG-3'
Pool random region: 30
Binding buffer/conditions: PBS = 10.1 mMNa2HPO4, 1.8 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH 7.4
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: 18006 Da
Post-SELEX modifications: Truncated
Application as quoted in the referenced paper: Detection: " Describe and characterize a set of high-affinity RNA ligands for bFGF that were selected from a pool of 10^14 molecules and show that these ligands inhibit binding of the growth factor to its cell-surface receptors. The idea that bFGF antagonists may have useful medicinal applications is not new (reviewed in ref. 5). bFGF is believed to play a key role in the development of smooth-muscle cell lesions following vascular injury. Overexpression of bFGF (and other members of the FGF family) is correlated with many malignant disorders"
Reference (1993, Proc Natl Acad Sci U S A ): Jellinek, D., Lynott, C. K., Rifkin, D. B., & Janjić, N. (1993). High-affinity RNA ligands to basic fibroblast growth factor inhibit receptor binding. Proceedings of the National Academy of Sciences of the United States of America, 90(23), 11227–11231. https://doi.org/10.1073/pnas.90.23.11227
Aptamer: 26A
Target: Basic fibroblast growth factor (bFGF)
Type of nucleic acid: ssRNA
Sequence: 5'GGGAGAUGCCUGUCGAGCAUGCUGCGUCAGAAGGCAACGUAUAGGCAAGCACACGUAGCUAAACAGCUUUGUCGACGGG3'
Sequence length: 79
GC content: 0.5569620253164557
Affinity: Kd: exhibits biphasic binding, 0.19 ± 0.02 nM, 49 ± 26 nM
Pool type: 5'-GGGAGAUGCCUGUCGAGCAUGCUG-N30-GUAGCUAAACAGCUUUGUCGACGGG-3'
Pool random region: 30
Binding buffer/conditions: PBS = 10.1 mMNa2HPO4, 1.8 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH 7.4
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: 18006 Da
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " Describe and characterize a set of high-affinity RNA ligands for bFGF that were selected from a pool of 10^14 molecules and show that these ligands inhibit binding of the growth factor to its cell-surface receptors. The idea that bFGF antagonists may have useful medicinal applications is not new (reviewed in ref. 5). bFGF is believed to play a key role in the development of smooth-muscle cell lesions following vascular injury. Overexpression of bFGF (and other members of the FGF family) is correlated with many malignant disorders"
Reference (1993, Proc Natl Acad Sci U S A ): Jellinek, D., Lynott, C. K., Rifkin, D. B., & Janjić, N. (1993). High-affinity RNA ligands to basic fibroblast growth factor inhibit receptor binding. Proceedings of the National Academy of Sciences of the United States of America, 90(23), 11227–11231. https://doi.org/10.1073/pnas.90.23.11227
Aptamer: 28B
Target: Basic fibroblast growth factor (bFGF)
Type of nucleic acid: ssRNA
Sequence: 5'GGGAGAUGCCUGUCGAGCAUGCUGAGGGUAACGUAUAGUCAAGACACCUCAAGUGUAGCUAAACAGCUUUGUCGACGGG3'
Sequence length: 79
GC content: 0.5189873417721519
Affinity: Kd: exhibits biphasic binding, 0.32 ± 0.07 nM, 140 ± 80 nM
Pool type: 5'-GGGAGAUGCCUGUCGAGCAUGCUG-N30-GUAGCUAAACAGCUUUGUCGACGGG-3'
Pool random region: 30
Binding buffer/conditions: PBS = 10.1 mMNa2HPO4, 1.8 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH 7.4
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: 18008 Da
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " Describe and characterize a set of high-affinity RNA ligands for bFGF that were selected from a pool of 10^14 molecules and show that these ligands inhibit binding of the growth factor to its cell-surface receptors. The idea that bFGF antagonists may have useful medicinal applications is not new (reviewed in ref. 5). bFGF is believed to play a key role in the development of smooth-muscle cell lesions following vascular injury. Overexpression of bFGF (and other members of the FGF family) is correlated with many malignant disorders"
Reference (1993, Proc Natl Acad Sci U S A ): Jellinek, D., Lynott, C. K., Rifkin, D. B., & Janjić, N. (1993). High-affinity RNA ligands to basic fibroblast growth factor inhibit receptor binding. Proceedings of the National Academy of Sciences of the United States of America, 90(23), 11227–11231. https://doi.org/10.1073/pnas.90.23.11227